Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

Johns Hopkins University47 enrolled

Overview

This research is being done to assess the long term prognosis of patients treated with ranibizumab for edema due to retinal vein occlusion.

People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer Eye Institute are followed up to assess long term outcomes

Study Type

OBSERVATIONAL

Enrollment

Conditions

Retinal Vein Occlusion

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients who have been enrolled in the following three trials will be included in the study: A) "A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein Occlusions.", B) "Extended follow-up of patients with macular edema due to bRanch rETinal vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with intravitreal ranibizumab (RETAIN) " C) "RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach (RELATE)" Exclusion Criteria: * None

Locations (1)

Wilmer Eye Institute

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Mean change from baseline in BCVA at 5 and 10 years.

Time frame: 10 years

Secondary Outcomes

Mean change from baseline in foveal thickness at 5 and 10 years

Time frame: 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.